Eris Lifesciences · NSE: ERIS · BSE: 540596
Q4 FY24 results · Jan–Mar 2024
Eris Lifesciences reported revenue from operations of ₹550.92 crore (up 36.8% from Q4 FY23) and net profit of ₹79.63 crore (up 29.5% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 550.92 | 402.80 | +36.8% | 486.30 | +13.3% |
| Other income | 15.15 | 1.00 | 15x | 4.20 | +260.9% |
| Total income | 566.07 | 403.80 | +40.2% | 490.49 | +15.4% |
| Profit before tax | 76.65 | 75.90 | +1.0% | 115.87 | −33.9% |
| Net profit for the period | 79.63 | 61.48 | +29.5% | 101.46 | −21.5% |
| Attributable to shareholders of the company | 70.96 | 65.42 | +8.5% | 102.74 | −30.9% |
| EPS, basic (₹) | 5.22 | 4.81 | +8.5% | 7.55 | −30.9% |
| Net margin (%) | 14.5 | 15.3 | 20.9 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 341.30 | 314.58 | +8.5% | 324.41 | +5.2% |
| Other income | 20.39 | 4.26 | +378.7% | 3.43 | +494.1% |
| Total income | 361.69 | 318.84 | +13.4% | 327.85 | +10.3% |
| Profit before tax | 41.75 | 95.51 | −56.3% | 34.64 | +20.5% |
| Net profit for the period | 39.51 | 87.84 | −55.0% | 31.66 | +24.8% |
| EPS, basic (₹) | 2.90 | 6.46 | −55.1% | 2.33 | +24.5% |
| Net margin (%) | 11.6 | 27.9 | 9.8 |
Consolidated
- Filed with BSE
- 23 May 2024, 11:02 IST
- Board meeting
- 21 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 May 2024, 11:02 IST
- Board meeting
- 21 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE